Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
784
datasets available to search
ShareScore release 0.9.0
Dataset results
784 results for “Tregs”
Multi-omics analysis reveals the link between Treg distribution and therapy efficacy in Hepatocellular Carcinoma patients treated with tremelimumab plus durvalumab
<p><strong><span><span>Introduction</span></span></strong></p> <p><span>Hepatocellular carcinoma (HCC) remains a significant contributor to cancer-related deaths. Immunotherapy, either alone or in combination, has emerged as the standard treatment for advanced HCC. Notably, the combination of durvalumab (dur) and tremelimumab (trem) has received FDA approval based on findings from the HIMALAYA trial. However, comprehensive studies elucidating immune responses are lacking. We conducted a thorough analysis utilizing clinical samples from tumor biopsies to understand the mechanism of response.</span></p> <p><strong><span><span>Methods</span></span></strong></p> <p><span>Multiplexed immunofluorescence microscopy was used to analyze immune cell infiltration in primary human liver cancer samples. We developed and validated a comprehensive 37-plex antibody panel for immunofluorescence imaging of human FFPE samples. We applied highly multiplexed co-detection by indexing (CODEX) technology to simultaneously profile in situ expression of 37 proteins at sub-cellular resolution in 20 HCC patient samples using whole slide scanning. We established an image analysis pipeline to quantify all major cell populations in the human liver using supervised manual gating and unsupervised clustering algorithms using the exported matrix of the marker expression and spatial information. Clinical metadata including sex, gender, ethnicity, pretreatment, and histopathological reports are available for all patient samples.</span></p> <p><strong><span><span>Results</span></span></strong></p> <p><span><span>Using high-dimensional spatially resolved quantitative analysis of multiplexed immunofluorescence microscopy images, we generated a unique dataset and profiled the single-cell pathology landscape for human HCC treated with immunotherapy. In situ phenotyping of 400,000 single cells (including 130,000 CD45+ immune cells) allowed for the quantification of cell phenotype clusters, differential analysis of activation markers, and spatial features of each individual cell. This analysis revealed the comprehensive profile of the cell composition and spatial interactions of different cells in the TiME of patients treated with immunotherapy. Further details on the study can be obtained in our paper once it’s published.</span></span></p> <p><strong><span><span>Conclusion</span></span></strong></p> <p><span><span>We developed the CODEX panel for FFPE biopsy samples of HCC patients.</span></span></p>
LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3
<p>Flow cytometry (Immune profiling) Tidy Data: Figure 1d,e, 2d</p> <p>ELISA Tidy Data: Figure 2c, 4b</p> <p>qRT-PCR Tidy Data: Figure 1b, 3a, 4c,d</p> <p>Cell count Tidy Data: Figure 2b</p> <p> </p> <p> </p>
Supplementary Figure 1 Gating strategy for Treg phenotype analysis.
<p><strong>Supplementary Figure 1. Gating strategy for Treg phenotype analysis. |</strong> Isolated and purified cells (see Methods) were analysed by flow cytometry with <strong>(A)</strong> gating performed as indicated including the exclusion of dead cells (by Live/Dead staining kit) and analysing only CD4+CD25+ double-positive cells. <strong>(B)</strong> These cells were then stained with indicated marker antibodies. The histogram quantification areas indicated by the black bars were set against control staining performed with non-specific isotype antibodies corresponding to each marker antibody.</p>
Oncogenic calreticulin induces TGF-β expression and Treg expansion in the bone marrow microenvironment as a mechanism of immune escape
<p>This repository contains all necessary scRNA-seq inputs to reproduce the results described in "Oncogenic calreticulin induces TGF-β expression and Treg expansion in the bone marrow microenvironment as a mechanism of immune escape" by Schmidt et al. (Cancer Research 2024). </p> <p>Content:</p> <ol> <li>"MPN_calreticulin_bm.R" --> R script containing all code</li> <li>"cells_table.RDS" --> cells table containing, cell_id, UMAP coordinates, complexity, cell type annotation and metadata</li> <li>"normalized_matrix.RDS" --> quality control filtered, log2-normalized and centered expression matrix</li> <li>"reference_signatures.RDS" --> all external signatures used for this study</li> <li>"EV2_*", "EV5_*", "MPN2_*", "MPN5_*", --> cellranger outputs</li> </ol>
KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer
<p><strong><span>Purpose</span></strong><span>: T<span>o identify predictive factors of nivolumab sensitivity, peripheral blood NKs and Tregs were evaluated </span>in patients with metastatic renal cancer (mRCC) enrolled in the REVOLUTION trial.</span></p> <p><strong><span>Experimental design:</span></strong><span> 57 mRCCs being treated with nivolumab, as at least second-line of therapy (REV), and 62 healthy donors (HDs) were longitudinally evaluated (</span><span>0-1-3-6-12 months</span><span>) for</span><span> peripheral NKs and Tregs, phenotype and function. </span><span>Multivariable logistic regression were conducted to identify the independent predictors. The </span><span>.632+ internal cross-validation was used to avoid overfitting. </span><span>The best cut-off value </span><span>based on three-months clinical-response</span><span> was applied to </span><span>progression-free survival (PFS)</span><span> and </span><span>overall survival (OS)</span><span>. Kaplan-Meier curves for PFS and OS were produced.</span></p> <p><strong><span>Results:</span></strong><span> </span><span>At pre-treatment, mRCCs displayed high frequency of <sup>NKp46+</sup>NKs, <sup>NKp30+</sup>NKs, <sup>KIR2DL1+</sup>NKs, <sup>KIR2DL2/DL3+</sup>NKs, and<sup> PD-1+</sup>NKs with reduced NK degranulation; as well as high frequency of Tregs, </span><sup><span>PD-1+</span></sup><span>Tregs,</span><sup><span> Helios+</span></sup><span>Tregs and </span><sup><span>ENTPD-1+</span></sup><span>Tregs</span><span>. Responder patients (R), identified as a clinical response after three-months of treatment,</span><span> presented at pre-treatment significantly low CD3<sup>+</sup>, high<sup> KIR2DL2/DL3+</sup></span><span>NKs</span><span>, high <sup>PD-1+</sup>Tregs and high <sup>Helios+</sup>Tregs. Upon multivariate analysis, only <sup>KIR2DL2/DL3</sup>NKs and <sup>Helios+</sup>Tregs held as independent predictors of nivolumab responsiveness. The <sup>KIR2DL2/DL3+</sup>NKs >35.3% identified patients with longer OS while the <sup>Helios+</sup>Tregs >34.3% displayed significantly longer PFS. After 1-month of nivolumab, R patients showed low CD3<sup>+</sup>, high NKs, <sup>KIR2DL2/DL3+</sup>NKs and <sup>ICOS+</sup>Tregs. Among these subpopulations, CD3<sup>+</sup> and <sup>KIR2DL2/DL3+</sup>NKs held as independent predictors of nivolumab efficacy. Low CD3<sup>+ </sup>(≤71%) significantly associated with longer PFS while high <sup>KIR2DL2/DL3+</sup>NKs (>23.3%) associated with both PFS and OS. </span></p> <p><strong><span>Conclusions:</span></strong><span> Pre-treatment evaluation of <sup>Helios+</sup>Tregs/<sup>KIR2DL2/DL3+</sup>NKs and one-month post-treatment CD3<sup>+</sup>/<sup> KIR2DL2/DL3+</sup>NKs will predict nivolumab response in mRCCs<span>.</span></span></p>
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
ClinicalTrials.gov study NCT01210664. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
ClinicalTrials.gov study NCT02474199. IPD Sharing: Not stated. Countries: 1. Publications: 2.
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
ClinicalTrials.gov study NCT01927120. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The transcriptomic landscape of Galectin-3-treated versus vehicle-treated Tregs
Open the record for dataset details and reuse information.
IL-32 producing CD8+ memory T cells and Tregs define the IDO1/PD-L1 niche in human cutaneous leishmaniasis skin lesions.
<p>https://github.com/NidhiSDey/leish-ME/</p> <p>Human cutaneous leishmaniasis (CL) is characterised by chronic skin pathology. Experimental and clinical data suggest that immune checkpoints (ICs) play a crucial role in disease outcome but the cellular and molecular niches that facilitate IC expression during leishmaniasis are ill-defined. We previously showed that in Sri Lankan patients with CL two ICs, indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) are enriched in lesional skin and that reduced PD-L1 expression early after treatment onset predicts cure rate following antimonial therapy. Here, we use spatial cell interaction mapping to identify IL-32-expressing CD8+ memory cells and regulatory T cells as key components of the IDO1 / PD-L1 niche in a cohort of Sri Lankan CL patients. This finding was confirmed in patients with distinct forms of dermal leishmaniasis in Brazil and India. Furthermore, in our Sri Lankan cohort the abundance of IL-32+ cells and IL-32+CD8+ T cells at treatment onset was prognostic for rate of cure. This study provides a unique spatial perspective on the expression of key ICs in these important skin diseases and a novel route to identify biomarkers of treatment response.</p>
Treg Specificity
<p>Revision imaging data with associated analysis code (https://github.com/npagane/treg_specificity). </p>
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
ClinicalTrials.gov study NCT04924491. IPD Sharing: NO. Countries: 1. Publications: 1.
The ONE Study UK Treg Trial
ClinicalTrials.gov study NCT02129881. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Low-dose IL-2 for Treg Expansion and Tolerance (LITE)
ClinicalTrials.gov study NCT02949492. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
ClinicalTrials.gov study NCT03716258. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Effects of Sevoflurane and Desflurane on Treg
ClinicalTrials.gov study NCT02559297. IPD Sharing: YES. Countries: 1. Publications: 13.
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
ClinicalTrials.gov study NCT05129410. IPD Sharing: NO. Countries: 1. Publications: 4.
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
ClinicalTrials.gov study NCT01513109. IPD Sharing: Not stated. Countries: 1. Publications: 34.
Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor
ClinicalTrials.gov study NCT03779399. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
ClinicalTrials.gov study NCT03249064. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.